Splash Beverage partners with Lupvindol to advance CannEpil via FDA veterinary pathway

Reuters2026/08/05 12:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Splash Beverage Group signed a development and collaboration deal with Lupvindol Biosciences to advance CannEpil via the FDA veterinary drug pathway.
Program targets companion-animal oncology, chronic pain management, with initial focus on dogs.
Lupvindol to run scientific development, product work, FDA regulatory strategy, including the INAD process, toward potential conditional approval.
Splash to fund milestones, lead commercialization strategy, retain ownership of study data, regulatory submissions, new IP, licensing rights.
Lupvindol to absorb the annual FDA sponsor fee through conditional approval unless sponsorship is transferred.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Splash Beverage Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050830PRIMZONEFULLFEED9804153) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Splash Beverage partners with Lupvindol to advance CannEpil via FDA veterinary pathway

You may also like

Crypto prices